- Home
- SEER vs OBIO Comparison
SEER vs OBIO Comparison
Compare SEER & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- OBIO
- Stock Information
- Founded
- SEER 2017
- OBIO 2017
- Country
- SEER United States
- OBIO United States
- Employees
- SEER 147
- OBIO N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- SEER Health Care
- OBIO Health Care
- Exchange
- SEER Nasdaq
- OBIO Nasdaq
- Market Cap
- SEER 135.0M
- OBIO 156.6M
- IPO Year
- SEER 2020
- OBIO N/A
- Fundamental
- Price
- SEER $2.29
- OBIO $5.28
- Analyst Decision
- SEER Hold
- OBIO Strong Buy
- Analyst Count
- SEER 1
- OBIO 5
- Target Price
- SEER $3.00
- OBIO $15.80
- AVG Volume (30 Days)
- SEER 200.2K
- OBIO 182.8K
- Earning Date
- SEER 02-27-2025
- OBIO 11-12-2024
- Dividend Yield
- SEER N/A
- OBIO N/A
- EPS Growth
- SEER N/A
- OBIO N/A
- EPS
- SEER N/A
- OBIO N/A
- Revenue
- SEER $14,608,000.00
- OBIO $2,647,000.00
- Revenue This Year
- SEER N/A
- OBIO $22.61
- Revenue Next Year
- SEER $34.78
- OBIO $16.64
- P/E Ratio
- SEER N/A
- OBIO N/A
- Revenue Growth
- SEER N/A
- OBIO N/A
- 52 Week Low
- SEER $1.51
- OBIO $3.96
- 52 Week High
- SEER $2.63
- OBIO $10.06
- Technical
- Relative Strength Index (RSI)
- SEER 45.45
- OBIO 50.69
- Support Level
- SEER $2.23
- OBIO $5.00
- Resistance Level
- SEER $2.37
- OBIO $5.70
- Average True Range (ATR)
- SEER 0.11
- OBIO 0.57
- MACD
- SEER -0.01
- OBIO 0.05
- Stochastic Oscillator
- SEER 41.43
- OBIO 56.41
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.